Table 7.6a

Immunosuppression Use for Induction, 1994 to 2003

Recipients with Pancreas After Kidney (PAK) Transplants

	Year of Transplant
	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
Transplants	54	67	113	130	157	221	303	307	377	343
Tx With Immunosuppression Info	54	67	109	129	153	218	297	305	374	333
No Induction Drugs Recorded	79.6%	52.2%	28.4%	26.4%	37.3%	33.5%	33.0%	25.6%	27.5%	26.1%
Drugs	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
ALG
ATG/NRATG/NRATS	1.9%	7.5%	45.9%	48.1%	19.6%	8.3%	1.7%	0.3%	2.4%	0.6%
OKT3	18.5%	40.3%	29.4%	24.8%	15.0%	8.7%	3.0%	0.7%	1.3%	0.9%
Thymoglobulin	0.0%	0.0%	0.0%	0.0%	0.7%	30.3%	37.4%	50.2%	51.6%	51.1%
Zenapax	0.0%	0.0%	0.0%	0.0%	26.1%	36.7%	32.7%	33.1%	25.1%	9.3%
Simulect	0.0%	0.0%	0.0%	0.8%	9.8%	10.6%	17.2%	13.1%	8.3%	8.1%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	13.2%

Source: OPTN/SRTR Data as of May 3, 2004.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.